Forma Therapeutics Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Forma Therapeutics stock.
View analyst ratings for Forma Therapeutics or view top-rated stocks.

Wall Street analysts have given Forma Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Forma Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Forma Therapeutics saw a decrease in short interest in May. As of May 28th, there was short interest totaling 2,790,000 shares, a decrease of 14.2% from the May 13th total of 3,250,000 shares. Based on an average trading volume of 400,600 shares, the days-to-cover ratio is currently 7.0 days. Currently, 7.3% of the shares of the stock are sold short.
View Forma Therapeutics' Short Interest.

Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Forma Therapeutics.

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) released its quarterly earnings data on Thursday, May, 13th. The company reported ($0.76) EPS for the quarter, meeting analysts' consensus estimates of ($0.76).
View Forma Therapeutics' earnings history.

6 Wall Street analysts have issued 12 month price targets for Forma Therapeutics' shares. Their forecasts range from $54.00 to $68.00. On average, they anticipate Forma Therapeutics' stock price to reach $59.83 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price.
View analysts' price targets for Forma Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Forma Therapeutics include Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Sana Biotechnology (SANA), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), Vericel (VCEL), NanoString Technologies (NSTG), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Bavarian Nordic A/S (BVNRY), Editas Medicine (EDIT) and Instil Bio (TIL).
View all of FMTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include The Boeing (BA), Marvell Technology (MRVL), The Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), The Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX).

(FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX."

Forma Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Cormorant Asset Management LP (9.96%), BlackRock Inc. (6.95%), Samsara BioCapital LLC (3.31%), Logos Global Management LP (2.98%), Janus Henderson Group PLC (1.79%) and Geode Capital Management LLC (0.91%).

FMTX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Credit Suisse AG, Citadel Advisors LLC, Russell Investments Group Ltd., Swiss National Bank, Marble Harbor Investment Counsel LLC, Bank of Montreal Can, and Chicago Partners Investment Group LLC.

FMTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Cormorant Asset Management LP, Samsara BioCapital LLC, Geode Capital Management LLC, Citigroup Inc., Northern Trust Corp, Rafferty Asset Management LLC, and Nuveen Asset Management LLC.

Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FMTX stock can currently be purchased for approximately $26.36.

Forma Therapeutics has a market capitalization of $1.25 billion and generates $100.56 million in revenue each year. The company earns $-70,410,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis.

Forma Therapeutics employs 114 workers across the globe.

The official website for Forma Therapeutics is www.formatherapeutics.com.

Forma Therapeutics is headquartered at 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472.

Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The company can be reached via phone at 617-679-1970 or via email at [email protected]